S1P Lyase: An Endogenous Suppressor of Pulmonary Fibrosis

S1P Lyase: An Endogenous Suppressor of Pulmonary Fibrosis

In this video from Thorax (the youtube channel of Thorax journal), watch Professor Viswanathan (Nati) Natarajan, from the University of Illinois, Chicago, talk about idiopathic pulmonary fibrosis, a chronic and progressive lung disease for which the prognosis is poor and diagnosis is difficult to conduct. Prof. Viswanathan’s…

Advanced 3-D Imaging Technique Used for First Time to View IPF in Lung Tissues

Researchers at the University of Southampton used an advanced, 3-D X-ray imaging technology for a first time on lung tissue samples from idiopathic pulmonary fibrosis (IPF) patients, gaining a better understanding of how the aggressive lung disease develops in the body. The study, “Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis” was published…

Karos’ Experimental Therapy for PAH and Fibrotic Diseases, KAR5585, Advances in Phase 1 Study

Karos Pharmaceuticals recently announced that its small molecule drug candidate, KAR5585, has advanced in Phase 1 clinical testing. The drug is being developed for the treatment of pulmonary arterial hypertension (PAH) and other diseases characterized by extensive fibrosis. KAR5585 received Orphan Drug designation for the treatment of PAH by the U.S. Food and Drug Administration…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums